---
title: "Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002821.SZ.md"
symbol: "002821.SZ"
name: "Asymchem Laboratories (Tianjin) Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T21:45:36.199Z"
locales:
  - [en](https://longbridge.com/en/quote/002821.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002821.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002821.SZ.md)
---

# Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ)

## Company Overview

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.asymchem.com.cn](https://www.asymchem.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 6 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 16.56% |  |
| Net Profit YoY | 11.74% |  |
| P/B Ratio | 2.39 |  |
| Dividend Ratio | 0.92% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 42820191529.04 |  |
| Revenue | 6924195167.34 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.32% | C |
| Profit Margin | 16.02% | A |
| Gross Margin | 43.02% | B |
| Revenue YoY | 16.56% | B |
| Net Profit YoY | 11.74% | C |
| Total Assets YoY | 6.47% | B |
| Net Assets YoY | 4.46% | C |
| Cash Flow Margin | 133.74% | B |
| OCF YoY | 16.56% | B |
| Turnover | 0.35 | D |
| Gearing Ratio | 13.25% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Asymchem Laboratories (Tianjin) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "16.56%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "11.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.39",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.92%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "42820191529.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "6924195167.34",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.32%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "16.02%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "43.02%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "16.56%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.74%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "6.47%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.46%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "133.74%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "16.56%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.35",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.25%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 38.32 | 88/215 | 38.32 | 34.94 | 32.45 |
| PB | 2.37 | 111/215 | 2.37 | 2.12 | 1.95 |
| PS (TTM) | 6.14 | 144/215 | 6.40 | 5.85 | 5.40 |
| Dividend Yield | 0.93% | 104/215 | 1.18% | 1.09% | 0.98% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-06T16:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 62% |
| Overweight | 3 | 23% |
| Hold | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 117.89 |
| Highest Target | 154.20 |
| Lowest Target | 115.43 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002821.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002821.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002821.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002821.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**